@ej23ny Biotech

Biotech posts on X about $xbi, $glmd, $ibb, $mreo the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

[--] Week [------] +78%
[--] Month [------] -53%
[--] Months [---------] +122%
[--] Year [---------] -16%

Mentions: [--] #

[--] Week [--] +5.30%
[--] Month [---] +4.60%
[--] Months [---] +115%
[--] Year [---] +21%

Followers: [-----] #

[--] Week [-----] -0.31%
[--] Month [-----] -0.17%
[--] Months [-----] +8.90%
[--] Year [-----] +12%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 63.28% cryptocurrencies 42.97% finance 42.19% technology brands 3.91% financial services 2.34% currencies 1.56% social networks 0.78% countries 0.78%

Social topic influence $xbi #7, $glmd #1, $ibb #2, $mreo #1, $rare #8, $hind #3, $adtx #5, $ibrx #49, $mten #4, $safx #5

Top accounts mentioned or mentioned by @quakerbrothers @daddimilton @madrigalpharma @vcu @idalopirdine @dball435 @drrichjlaw @boogeymantradez @abbvie @javier944712106 @liteupthedark1 @jeromeleonard5 @biotechiq @lovingpharma @meremrtl @amgen @abbottlab @exactsciences @orbimed @galmedpharma

Top assets mentioned SuperRare (RARE) ADiTx Therapeutics, Inc. (ADTX) ImmunityBio, Inc. Common Stock (IBRX) Mingteng International Corporation Inc. (MTEN) XCF Global, Inc. Class A Common Stock (SAFX) Viking Therapeutics, Inc (VKTX) KULR Technology Group, Inc. (KULR) Gains Network (GNS) MEDIROM Healthcare Technologies Inc. (MRM) Wave Life Sciences Ltd. Ordinary Shares (WVE) Bata (BTA) Innovation Beverage Group Limited (IBG) Oscar Health, Inc. (OSCR) Opendoor Technologies Inc Common Stock (OPEN) Fractyl Health, Inc. (GUTS) BEAM (BEAM) GSK plc (GSK) Intellia Therapeutics, Inc (NTLA) Terns Pharmaceuticals, Inc. (TERN) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Autozi Internet Technology (Global) Ltd. (AZI) Intensity Therapeutics, Inc. (INTS) BioMarin Pharmaceutical, Inc. (BMRN) Goldman Sachs (GS) Structure Therapeutics Inc. (GPCR) Top Wealth Group Holding Limited (TWG) Treasure Global Inc (TGL) VCI Global Limited (VCIG)

Top Social Posts

Top posts by engagements in the last [--] hours

"$MREO Im holding full position. I didnt sell at $5 or .20 I will continue hold it until the buy out. Rubric capital has been holding their position for 4-5 years You do you $XBI $IBB $MREO $RARE setrusumab is active drug in OI and better drug than Bisphosphonate which has been approved in [----] $XBI $IBB $MREO $RARE setrusumab is active drug in OI and better drug than Bisphosphonate which has been approved in [----] $XBI $IBB"
X Link 2026-01-14T18:17Z [----] followers, [----] engagements

"$MREO the wheels have not fallen off yet. IMHO NDA filing in [----] and approval in [----] @ej23ny https://t.co/ppXmO02DuU @ej23ny https://t.co/ppXmO02DuU"
X Link 2026-02-12T13:09Z [----] followers, [----] engagements

"$AZTR its ridiculous the stock price is trading .43 even with 1000% upside the market cap still would be cheap: At $5 per share 5.2M OS roughly $26M for biotech is very cheap. $FGL $INTS $MSPR $Mbrx $MBIO $OPEN $ASST $AZTR I think they are waiting with a press release because they are close to an merger agreement or founding. This can be next 1000% stock $open $bynd $AZTR I think they are waiting with a press release because they are close to an merger agreement or founding. This can be next 1000% stock $open $bynd"
X Link 2025-11-06T16:47Z [----] followers, [----] engagements

"@jeromeleonard5 Off course there is: $MREO $RARE trial was outdated with current FDA guidelines for OI $AMGN phase [--] OI trial Primary ends point Fracture BMD Z Score Secondly same story with $CMPX you was bearish and I was bullish when the was trading below $1 https://clinicaltrials.gov/study/NCT05972551term=Romosozumab%20Osteogenesis%20Imperfecta&rank=1 https://clinicaltrials.gov/study/NCT05972551term=Romosozumab%20Osteogenesis%20Imperfecta&rank=1"
X Link 2025-12-31T18:45Z [----] followers, [---] engagements

"@_Biotech_iQ @Loving_pharma $MREO High risk trade at .20 Alvelestat $0 - INBX-101 augmentation therapy sold $1.7Bn Navicixizumab similar MOA as $CMPX CTX-009 (tovecimig)"
X Link 2026-01-11T02:13Z [----] followers, [---] engagements

"$MREO $RARE NO FDA or EMA approved drug forOI.The disease is so devastating fda will face pushback from patients if the drug doesnt get approved $MLTX phase [--] VELA results were worst case scenario and still approvable drug $XBI $IBB @idalopirdine @ej23ny $MLTX will have a saleable drug; $MREO I have my doubts @idalopirdine @ej23ny $MLTX will have a saleable drug; $MREO I have my doubts"
X Link 2026-01-13T19:10Z [----] followers, [----] engagements

"$MREO Alvelestat pill - [--] randomized controlled Ph [--] in #AATD only small molecule succeed in mid stage in AATD No competition in oral pill after $BMRN discontinued $BMRN discards liver disease candidate after $4.8B Amicus announcement $XBI $IBB https://www.fiercebiotech.com/biotech/biomarin-quietly-discards-liver-disease-candidate-after-48b-amicus-announcement https://www.fiercebiotech.com/biotech/biomarin-quietly-discards-liver-disease-candidate-after-48b-amicus-announcement"
X Link 2026-01-20T18:02Z [----] followers, [----] engagements

"@Dball435 Alvelestat is more attractive now after BMRN discontinued"
X Link 2026-01-20T18:47Z [----] followers, [---] engagements

"@drrichjlaw Insane valuation: $EIKN already raised $1B+ in private funding +$318M IPO almost $1.5Bn. Probably the market cap would be $2B+"
X Link 2026-01-31T20:32Z [----] followers, [----] engagements

"$MREO unbelievable no reaction on $GSK return the rights to WVE-006 to $WVE $MREO Alvelestat should get more attention from big pharmaceuticals etc $GSK $SNY $XBI $IBB As I predicted while back $GSK would walk away from WVE-006 $WVE As I predicted while back $GSK would walk away from WVE-006 $WVE"
X Link 2026-02-02T19:34Z [----] followers, [----] engagements

"$MREO the stock price should have been up at least 100% Alvelestate remains the 👑 WVE [----] #AATD September [----] data was well below expectations and thats why $GSK waked away Take look at my comment in September 👇 $XBI $IBB $BEAM $NTLA $VRTX $MREO $MREO 👍 great news Alvelestat Still the leader in #AATD $WVE today reported phase [--] data which wasnt good. Not surprised though $XBI $IBB $MREO $MREO 👍 great news Alvelestat Still the leader in #AATD $WVE today reported phase [--] data which wasnt good. Not surprised though $XBI $IBB"
X Link 2026-02-02T19:53Z [----] followers, [----] engagements

"$EIKN @drrichjlaw correction 50.45M shares outstanding immediately after trading publicly The market cap would be roughly $8.5B @drrichjlaw Insane valuation: $EIKN already raised $1B+ in private funding +$318M IPO almost $1.5Bn. Probably the market cap would be $2B+ @drrichjlaw Insane valuation: $EIKN already raised $1B+ in private funding +$318M IPO almost $1.5Bn. Probably the market cap would be $2B+"
X Link 2026-02-02T22:25Z [----] followers, [----] engagements

"$MREO $RARE the data looked solid in IMHO Setrusumab hit the most important BMD And reduced fracture in children High chance of approval imho $XBI $IBB $MREO: Ultragenyx has earnings call on Feb [--]. This is the first time they will be answering a broader group of analysts about Setrusumab failure and the path forward. They now had more than a month to analyze the data so hopefully we will know the plans forward $MREO: Ultragenyx has earnings call on Feb [--]. This is the first time they will be answering a broader group of analysts about Setrusumab failure and the path forward. They now had"
X Link 2026-02-09T21:25Z [----] followers, [----] engagements

"$MREO $RARE osteogenesis imperfecta is debilitating disease and no approved treatment The only drug that has shown promising results in OI is Setrusumab Lets hope the FDA does the right thing and approve setrusumab Its painful to watch child suffering with OI 👇 Cam kemik hastas bir bebein annesi ile oynad yatakta kayma oyunu https://t.co/tzgqOObamw Cam kemik hastas bir bebein annesi ile oynad yatakta kayma oyunu https://t.co/tzgqOObamw"
X Link 2026-02-09T21:41Z [----] followers, [----] engagements

"$ABP 👍 THE GOLDMAN SACHS GROUP INC purchased [---------] shares representing 6.8% ownership"
X Link 2026-02-10T03:37Z [----] followers, [----] engagements

"@Quakerbrothers 😂 you are fixated with market cap. I told while back the current OS is around [---] -7M shares"
X Link 2026-02-12T21:16Z [----] followers, [--] engagements

"$GLMD $5M market cap Multiple assets: Phase [--] ready #MASH Phase [--] ready #MASH combo Phase 1/2 Aramchol and Stivarga HCC $TERN $4Bn market cap [--] asset TERN-701 phase [--] CML $XBI $IBB $ATON $MDGL $VKTX $GLMD holding full position low float any day could skyrocket: Cash in hand/$3 per share #MASH Pipeline is worth $0 which is ridiculous IMHO acquisition price target $10+ Will @MadrigalPharma acquire $GLMD $XBI $IBB $ATON $MDGL $VKTX $TERN $GLMD holding full position low float any day could skyrocket: Cash in hand/$3 per share #MASH Pipeline is worth $0 which is ridiculous IMHO acquisition price"
X Link 2026-01-13T14:44Z [----] followers, [----] engagements

"$GLMD still holding full position and I have not sold any shares and Im not planning to sell any Market makers still trying to hold the stock price down $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $GLMD waiting patiently for skyrocket like $SHPH $GLMD 5.5M OS news could come any day $XBI $IBB $GLMD waiting patiently for skyrocket like $SHPH $GLMD 5.5M OS news could come any day $XBI $IBB"
X Link 2026-01-20T20:36Z [----] followers, [----] engagements

"$GLMD $5.5M market cap dirt cheap The cheapest #MASH company With lead asset could be worth billion No debt and toxic warranties $19M in cash $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $GLMD its ridiculous low volume. Very easy to manipulate the stock price. today volume [----] $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE https://t.co/37j1OrTAcd $GLMD its ridiculous low volume. Very easy to manipulate the stock price. today volume [----] $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE https://t.co/37j1OrTAcd"
X Link 2026-01-22T19:55Z [----] followers, [----] engagements

"$GLMD is trading well below cash on hand $3 per share: Current price .85 Cash on hand $19M Roughly $3 per share without value the pipeline $HIND $ADTX $MRNO $GLMD current stock price .81 raised $7M at average price of $2 per share. During the [--] months ended September [--] [----] we sold [-------] ordinary shares pursuant to the [----] Sales Agreement for a total net consideration of approximately $7.7 million $XBI $HIND $ADTX https://t.co/Q5OnhRQM8O $GLMD current stock price .81 raised $7M at average price of $2 per share. During the [--] months ended September [--] [----] we sold [-------] ordinary shares"
X Link 2026-01-27T22:27Z [----] followers, [----] engagements

"$GLMD patiently waiting and still holding a full position. $HIND $ADTX $MRNO $GLMD added more today $GLMD added more today"
X Link 2026-02-02T17:11Z [----] followers, [---] engagements

"$GLMD reverse split in planning absolutely not in planning. The company has [--] months to get the stock price above $1 The extremely undervalued and stock price could skyrocket any day $HIND $ADTX $MRNO $GLMD reverse split in planning $GLMD reverse split in planning"
X Link 2026-02-02T18:22Z [----] followers, [----] engagements

"As I predicted while back $GSK would walk away from WVE-006 $WVE $wve regains full rights to #RNAediting AATD program from GSK as GSK selects another target under collaboration. https://t.co/Ooxjhg7nQf $KRRO $BEAM $wve regains full rights to #RNAediting AATD program from GSK as GSK selects another target under collaboration. https://t.co/Ooxjhg7nQf $KRRO $BEAM"
X Link 2026-02-02T19:18Z [----] followers, [----] engagements

"$GLMD holding full position Market cap $4M is completely a joke Cash as of 09:30:25 $19M Promising Data Seen with Aramchol in Combo with TKI Showing Potential in GI and Hepatic Cancers Potentially starting open label Phase 1b trial in 1st qtr [----] $HIND $ADTX $MRNO $XBI $GLMD reverse split in planning absolutely not in planning. The company has [--] months to get the stock price above $1 The extremely undervalued and stock price could skyrocket any day $HIND $ADTX $MRNO $GLMD reverse split in planning absolutely not in planning. The company has [--] months to get the stock price above $1 The"
X Link 2026-02-04T14:04Z [----] followers, [---] engagements

"$GLMD added more scope up dip $HIND $ADTX $MRNO $XBI $GLMD reverse split in planning absolutely not in planning. The company has [--] months to get the stock price above $1 The extremely undervalued and stock price could skyrocket any day $HIND $ADTX $MRNO $GLMD reverse split in planning absolutely not in planning. The company has [--] months to get the stock price above $1 The extremely undervalued and stock price could skyrocket any day $HIND $ADTX $MRNO"
X Link 2026-02-04T15:01Z [----] followers, [----] engagements

"$GLMD adding more .65 $HIND $ADTX $MRNO $XBI $GLMD added more scope up dip $HIND $ADTX $MRNO $XBI https://t.co/738OxkqIUM $GLMD added more scope up dip $HIND $ADTX $MRNO $XBI https://t.co/738OxkqIUM"
X Link 2026-02-04T15:23Z [----] followers, [----] engagements

"$GLMD current price .65 : raised $7M at average price of $2 per share $HIND current price $2.35 raised $5.29M at average price of $5 per share $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $GLMD current stock price .81 raised $7M at average price of $2 per share. During the [--] months ended September [--] [----] we sold [-------] ordinary shares pursuant to the [----] Sales Agreement for a total net consideration of approximately $7.7 million $XBI $HIND $ADTX https://t.co/Q5OnhRQM8O $GLMD current stock price .81 raised $7M at average price of $2 per share. During the"
X Link 2026-02-04T18:05Z [----] followers, [----] engagements

"Low float $GLMD -4% I expect reversal $HIND +22% $XBI $IBB $GLMD current price .65 : raised $7M at average price of $2 per share $HIND current price $2.35 raised $5.29M at average price of $5 per share $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX https://t.co/jyRyN9erex $GLMD current price .65 : raised $7M at average price of $2 per share $HIND current price $2.35 raised $5.29M at average price of $5 per share $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX https://t.co/jyRyN9erex"
X Link 2026-02-04T19:36Z [----] followers, [----] engagements

"$GLMD adding more today. Scooping up the dip $HIND $ADTX $MRNO $XBI $GLMD adding more .65 $HIND $ADTX $MRNO $XBI https://t.co/OaJbdibXag $GLMD adding more .65 $HIND $ADTX $MRNO $XBI https://t.co/OaJbdibXag"
X Link 2026-02-05T19:01Z [----] followers, [----] engagements

"$GLMD loaded up last couple of days: Yahoo Finance Financial Highlights of $Glmd Total Cash $19M Book Value Per Share $3.49 $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $HIND $GLMD adding more today. Scooping up the dip $HIND $ADTX $MRNO $XBI https://t.co/YdJxeHjk35 $GLMD adding more today. Scooping up the dip $HIND $ADTX $MRNO $XBI https://t.co/YdJxeHjk35"
X Link 2026-02-06T14:49Z [----] followers, [----] engagements

"$GLMD IMHO extremely high rewards at this level and low risk. Cash in hand is at least $2 yahoo has $3.49 per share $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $HIND $GLMD loaded up last couple of days: Yahoo Finance Financial Highlights of $Glmd Total Cash $19M Book Value Per Share $3.49 $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $HIND https://t.co/V5pc5SZLps $GLMD loaded up last couple of days: Yahoo Finance Financial Highlights of $Glmd Total Cash $19M Book Value Per Share $3.49 $KULR $SAFX $SRXH $SCNX $MTEN $IVP"
X Link 2026-02-09T15:21Z [----] followers, [---] engagements

"$GLMD abstract published of lead asset Aramchol. Results looking promising Next step the company and sponsor is designing phase [--] trial $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $HIND https://x.com/oncotarget/status/2002091681785462940s=46 🎥 #OncotargetShort: Abstract #video about this #research paper #published in Vol. [--] titled "The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo." @VCU 🔗 https://t.co/nNfAzMdKjL #cancer #TrendingWithImpact #tumors #oncology #oa https://t.co/8pOfoKuifh"
X Link 2026-02-09T19:48Z [----] followers, [----] engagements

"My favorite low float stocks $GLMD big position on my portfolio [---] to 11M OS $HIND 6M OS $QTTB [----] OS $XBI $IBB Low float $GLMD -4% I expect reversal $HIND +22% $XBI $IBB Low float $GLMD -4% I expect reversal $HIND +22% $XBI $IBB"
X Link 2026-02-09T20:21Z [----] followers, [----] engagements

"$MREO we will find out tomorrow Setrusumab if it path forward for filing. IMHO i think it strong possibility that they will file for approval EU approval is much easier than FDA Eu has warnings label regarding rare atypical femoral fractures caused bisphosphonate $XBI $IBB"
X Link 2026-02-11T13:24Z [----] followers, [----] engagements

"$GLMD very low risk of dilution 6.6M OS $19M in cash As of 02/9/26 $2.8 per share vs current stock price of .65 $XBI $IBB $HIND $QTTR My favorite low float stocks $GLMD big position on my portfolio [---] to 11M OS $HIND 6M OS $QTTB [----] OS $XBI $IBB My favorite low float stocks $GLMD big position on my portfolio [---] to 11M OS $HIND 6M OS $QTTB [----] OS $XBI $IBB"
X Link 2026-02-11T18:03Z [----] followers, [---] engagements

"$GLMD no debt no toxic financing Should be trading same price as $QTTB Current OS 6.6M confirmed by the company Cash in hand roughly $18M as of December [----] Phase [--] ready #MASH asset $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $HIND My favorite low float stocks $GLMD big position on my portfolio [---] to 11M OS $HIND 6M OS $QTTB [----] OS $XBI $IBB My favorite low float stocks $GLMD big position on my portfolio [---] to 11M OS $HIND 6M OS $QTTB [----] OS $XBI $IBB"
X Link 2026-02-12T17:18Z [----] followers, [----] engagements

"$GLMD still long on the stock despite downtrend but the undervalued. Here are some low OS $GLMD. 6.6M OS SP .58 $HIND 5.5M OS SP $2.7 $QTTB. 12.5M OS SP $3.9 $XBI $IBB $GLMD text book manipulation big discrepancy between buy and sell [-----] buy order at .609 and sell at .656 $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $HIND $QTTB https://t.co/PEaUnKc1Z1 $GLMD text book manipulation big discrepancy between buy and sell [-----] buy order at .609 and sell at .656 $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $HIND $QTTB"
X Link 2026-02-13T15:38Z [----] followers, [---] engagements

"$GLMD text book manipulation big discrepancy between buy and sell [-----] buy order at .609 and sell at .656 $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $HIND $QTTB $GLMD no debt no toxic financing Should be trading same price as $QTTB Current OS 6.6M confirmed by the company Cash in hand roughly $18M as of December [----] Phase [--] ready #MASH asset $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX $ADTX $HIND https://t.co/D45aBEO8qV $GLMD no debt no toxic financing Should be trading same price as $QTTB Current OS 6.6M confirmed by the company"
X Link 2026-02-12T19:34Z [----] followers, [----] engagements

"$MREO Rubric capital filed yesterday 13F Holding full position in the company no changes Im guess that they believe the company still worth at least $5-$10 $5 the valuation would be $900m $10 the valuation would be 1.8Bn Im holding full position as well. $XBI $IBB $MREO Im holding full position. I didnt sell at $5 or .20 I will continue hold it until the buy out. Rubric capital has been holding their position for 4-5 years You do you $XBI $IBB $MREO Im holding full position. I didnt sell at $5 or .20 I will continue hold it until the buy out. Rubric capital has been holding their position for"
X Link 2026-02-14T17:26Z [----] followers, [----] engagements

"$AZTR reported good quarter. No public offering because they already have $20M in financing"
X Link 2025-11-12T23:28Z [----] followers, [----] engagements

"$GLMD great 3rd quarter *current price .84 vs $3.49 valuation * $4.5M market cap * $19.2M in cash /5.5M OS $3.49 per share $EPSM $ASST $GNS $AZI $EPWK $BULL $smx $glto $amix $VEEE $FGL $SBEV $ADTX $JAGX $SGBX $KALA $XBI"
X Link 2025-11-26T16:06Z [----] followers, [---] engagements

"$MREO next to report phase [--] data December data readout $KYMR +51% $DYN +13% $GPCR +102% $WVE +137% $MREO to report phase [--] data imminent"
X Link 2025-12-08T17:21Z [----] followers, [---] engagements

"$GLMD $6M market cap & $19.2M in cash -p [--] ready MASH drug -p 1/2 oncology asset The company trading negative enterprise value Cash in hand /$3 per share $TERN beginning of year was traded $1.87 and now trading $45 discontinued main obesity drug in October $XBI $IBB"
X Link 2025-12-12T15:05Z [----] followers, [----] engagements

"$MREO $RARE another foolish tweet by male nurse @meremrtl few weeks before phase [--] results. The fracture rate was 67% in phase [--] They need 30% fractures rates to to be successful plenty of room for margin of error"
X Link 2025-12-15T19:45Z [----] followers, [----] engagements

"$MREO $RARE huge opportunity for Setrusumab similar or higher price than Crysvita Canada Reimbursement Recommendation (Crysvita) Crysvita estimated cost the public drug approximately $287000000 over the next [--] years How much does Crysvita cost 410K-$528k per patient $MREO $RARE the biggest binary catalyst $MREO $RARE the biggest binary catalyst"
X Link 2025-12-21T01:34Z [----] followers, [----] engagements

"$GLMD just matter of time when stock skyrocket. Holding full position Trading well below cash in hand $3.49 per share $PAVS $FULC $WKHS $CETX $TWG $TGL $VCIG $IBIO $QCLS $IRBT $SGML $NCPL $XBI $IRBT $pfsa $SGBX $GLMD reversing after a downtrend eyes on follow-through https://t.co/jORGfABM2L $GLMD reversing after a downtrend eyes on follow-through https://t.co/jORGfABM2L"
X Link 2025-12-22T18:52Z [----] followers, [----] engagements

"$RARE will be acquired by @Amgen 1) setrusumab is superior than @Amgen Romosozumab. 2) Setrusumab phase [--] will readout positive 3) Bisphosphonates aka Fosamax dont make bone stronger and could lead to femur fracture Good luck"
X Link 2025-12-26T17:51Z [----] followers, [----] engagements

"@idalopirdine 👍. Unfortunately people are bullish on $MLTX NDA and bearish on $MREO NDA which doesnt make any sense to me. They are so many folks who are clueless interpreting the data"
X Link 2026-01-13T18:20Z [----] followers, [---] engagements

"$CMPX hit [--] weeks high today $6.14: I feel bad for folks who sold it $1.90: I guess next @ej23ny Sold $cmpx 190$ for a slight profit. Turned bearish for good reasons. And that ORR drop on topline proved me right. Didn't think they would still hit stat sig below [--] tbh. No regrets as it wasn't worth the risk. They'll also need to run another P3 imo. Wait for it. @ej23ny Sold $cmpx 190$ for a slight profit. Turned bearish for good reasons. And that ORR drop on topline proved me right. Didn't think they would still hit stat sig below [--] tbh. No regrets as it wasn't worth the risk. They'll also"
X Link 2026-01-14T22:21Z [----] followers, [----] engagements

"$MREO 👍 Setrusumab phase [--] robust data BMD and pain improvements in OI. The stock price should continue to increase into $1-$5 and potential to buy out of $10+ $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE"
X Link 2026-01-15T13:04Z [----] followers, [----] engagements

"$MREO volatility continues: institutional investors are loading up because data looks approvable [------] shares buys at .68 $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $TENX $MREO 👍 Setrusumab phase [--] robust data BMD and pain improvements in OI. The stock price should continue to increase into $1-$5 and potential to buy out of $10+ $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $MREO 👍 Setrusumab phase [--] robust data BMD and pain improvements in OI. The stock price should continue to increase into $1-$5 and potential to buy out of $10+ $KULR"
X Link 2026-01-15T19:35Z [----] followers, [----] engagements

"$MREO $86M market cap High risk 1) Alvelestat $0 - INBX-101 augmentation therapy sold $1.7Bn 2) Navicixizumab similar MOA as $CMPX CTX-009 (tovecimig) valued +$1B $XBI $IBB $MREO Why it could bounce back Oversold: Technical RSI at extreme lows. Strategic Pivot: Focus moving to Alvelestat Burn Rate: extends survival to [----]. M&A target for larger players interested in rare disease IP. High risk but look decoupled from the remaining assets. 🧪💎 $MREO Why it could bounce back Oversold: Technical RSI at extreme lows. Strategic Pivot: Focus moving to Alvelestat Burn Rate: extends survival to"
X Link 2026-01-21T19:53Z [----] followers, [----] engagements

"$MREO $RARE overall both phase [--] COSMIC study ORBIT reported solid data which is noted by J.P Morgan as well. Orbit pain score was very positive 2/10 $XBI $IBB $MREO surprised nobody posted this released https://t.co/BKQi0DY6lf $MREO surprised nobody posted this released https://t.co/BKQi0DY6lf"
X Link 2026-01-22T13:18Z [----] followers, [----] engagements

"$MREO $RARE BMDsurrogate endpoint by fda will this applied on OI Personally I think so but we will find very shortly No approved drug in OI & Setru is better than bisphos BMD is linked to reduced risk of vertebral & hip fractures for that reason Setru will be approved $xbi $RARE WF Our Call on $RARE think there's a potential for the BMD data to carry setrusumab through the FDA.The link between fracture rates and Bone Mineral Density in OI isn't perfect but it's also not zero and the stock pullback creates a good entry point. PoS=50%. stock is $RARE WF Our Call on $RARE think there's a"
X Link 2026-01-23T18:10Z [----] followers, [----] engagements

"$MREO nothing less then $5 $10 price target looks unrealistic for most Setru potentially commercialized in [----]. Anything is possible $CRVS congrats to long rise it from $2 to $26 less then [--] years based on phase [--] data. Long way to commercialization etc at least [--] trials $MREO - Gloves are off w DSK & Rubric now must wait for $RARE to go to FDA. I expect Rubric will pressure for a monetization. My guess a sale + CVR in [----]. Unless DSK has a blckbstr deal on table. MREO will be no more. Dreams of commercial org w sales force do not make sense. $MREO - Gloves are off w DSK & Rubric now must"
X Link 2026-01-23T18:42Z [----] followers, [----] engagements

"$MREO $RARE probably Advocates for OI disease will push the FDA to approve a breakthrough Setrusumab. Setrusumab Good safety and strong BMD data will be enough for FDA approval and EU. $QURE $XBI $IBB Advocates for Huntingtons disease are pressing the FDA to approve a breakthrough gene therapy under Right-to-Try. The push follows data showing the treatment may significantly slow disease progression. $QURE $WVE $SRPT https://t.co/BOSeByYJV8 Advocates for Huntingtons disease are pressing the FDA to approve a breakthrough gene therapy under Right-to-Try. The push follows data showing the"
X Link 2026-01-26T18:51Z [----] followers, [----] engagements

"$MREO $RARE WOW great summary of Bisphosphonates: -Huge safety concerns -efficiency not that good -should not be used as maintenance therapy Strength the case of Setrusumab in OI and should be approved by FDA and EU 🦴 Stopping antiresorptives in osteoporosis 🔹 Bisphosphonates Bind bone residual effect after stop BMD gain plateaus [--] yrs Drug holiday OK if LOWMOD risk Continue if: age [--] T-score [---] prior fracture Tail effect: Zoledronate Alendronate https://t.co/dXKF4lu3se 🦴 Stopping antiresorptives in osteoporosis 🔹 Bisphosphonates Bind bone residual effect after stop BMD gain plateaus"
X Link 2026-01-29T03:59Z [----] followers, [----] engagements

"$MREO its ridiculous that Alvelestat has $0 value despite good results in severe alpha-1 antitrypsin deficiency. #AATD [--] randomized controlled phase [--] trials [---] patients. -Favorable safety profile -good efficacy $WVE $Beam $prme $NTLA $XBI Eur Respir J: Alvelestat an oral neutrophil elastase (NE) inhibitor demonstrated a favourable safety profile suppressed NE and improved disease activity biomarkers when taken at [---] mg twice daily for [--] weeks in severe alpha-1 antitrypsin deficiencyhttps://t.co/LTZEC7APKl https://t.co/7cc0dJpJa8 Eur Respir J: Alvelestat an oral neutrophil elastase (NE)"
X Link 2026-01-29T13:39Z [----] followers, [----] engagements

"$MREO Alvelestat Chronic treatment of AATD disease etc early and late stage of #AATD Currently is the only small molecule advancing into phase [--] #AATD is very difficult to be cured specially #AATD lung disease by $BEAM $WVE $XBI $IBB $MREO its ridiculous that Alvelestat has $0 value despite good results in severe alpha-1 antitrypsin deficiency. #AATD [--] randomized controlled phase [--] trials [---] patients. -Favorable safety profile -good efficacy $WVE $Beam $prme $NTLA $XBI $MREO its ridiculous that Alvelestat has $0 value despite good results in severe alpha-1 antitrypsin deficiency. #AATD 2"
X Link 2026-01-30T17:35Z [----] followers, [----] engagements

"@boogeymantradez Absolutely not similar $QNCX to $MREO Lucid Capital Markets double downgrades on $QNCX from $8 to $0 price target. Running out of cash"
X Link 2026-01-31T13:02Z [----] followers, [---] engagements

"@boogeymantradez Young man: Im just giving you heads up that $QNCX is extremely risky"
X Link 2026-01-31T14:42Z [----] followers, [---] engagements

"@Quakerbrothers 5.6+.65 =3.6"
X Link 2026-02-05T00:27Z [----] followers, [--] engagements

"@Quakerbrothers 😂 its not worth responding to your tweets. Yahoo has the market cap 3.47M"
X Link 2026-02-05T01:31Z [----] followers, [--] engagements

"@Quakerbrothers EIKN was calculations error"
X Link 2026-02-05T01:31Z [----] followers, [--] engagements

"$tomdf Todos Medical Announces $23760000 Contract for COVID-19 PCR Testing Equipment @AbbottLab @ExactSciences $abt $exas $srne $aytu #COVID19 #covid #pennystocks #otcstocks $ibio $htbx $nvax $mrna https://www.streetinsider.com/dr/news.phpid=17305873 https://www.streetinsider.com/dr/news.phpid=17305873"
X Link 2020-08-31T12:15Z [----] followers, [--] engagements

"@OrbiMed $MREO partner $RARE presented impressive presentation on Setrusumab $MREO will Receive up to $254M for clinical regulatory and commercial milestones +double digit royalties on net sales in US.Mereo retains rights to setrusumab in EU&UK potential value +500M $XBI $IBB"
X Link 2023-01-11T16:52Z [----] followers, 33.2K engagements

"$MREO multiple interim analysis built into the trial most likely the trial will be stopped early than primary completion date of 03/2025. The fracture rate reduction 3X and the trial overpowered will result early stoppage $XBI $IBB 1/ A few interesting notes on Setrusumab following the $RARE conference call relevant to $MREO: A few of the questions were regarding the timing on the two ORBIT interim analysis and Emil hasnt been very forthcoming but seems to have finally given some details. 1/ A few interesting notes on Setrusumab following the $RARE conference call relevant to $MREO: A few of"
X Link 2023-11-03T12:09Z [----] followers, [----] engagements

"$MREO speachless that the stock price is stuck $3s Despite postive news on #TIGIT -Just #TIGIT asset alone could be worth at least $5 per share Phase 1/2 etigilimab #TIGIT in combination with nivolumab in select recurrent advanced / metastatic solid tumors -impressive clinical efficacy and deep durable responses Great video by Principal Investigator of ACTIVATE a Phase 1b/2 basket etigilimab #TIGIT in combination with nivolumab $XBI $IBB $NVS $ITOS $BGNE https://www.onclive.com/view/dr-mckean-on-the-activate-study-in-solid-tumors-and-pd-l1-low-disease Piper $ITOS Remain buyers based potential"
X Link 2024-03-07T15:16Z [----] followers, [----] engagements

"$INSM hit [--] wk high $81.25 / $15B market cap $MREO $3.06 /$475M Alvelestat - similar MOA as $INSM Brensocatib #Bronchiectasis I will make bold predictions based on my opinion that Alvelestat is similar or better than $INSM Benscoatib $XBI $IBB $AZN $NVS $GSK $BYM $MREO $460M MCAP : Ridiculous low 25X cheaper than $INSM Alvelestat - similar MOA as $INSM Brensocatib According to Baird report PH [--] READY IN #AATD potentially Future indication #COPD #Bronchiectasis $INSM $14B MCAP Brensocatib- Bronchiectasis $XBI $IBB $gsk $AZN $NVS https://t.co/vbpm2nH7L8 $MREO $460M MCAP : Ridiculous low 25X"
X Link 2025-02-04T16:47Z [----] followers, 12.8K engagements

"$ABP $16M market cap Developing ABP-150 Claudin [----] in Gastric cancer $IMAB stock price increased from .60 to $5.90 based on givastomig Claudin18.2 asset in gastric cancer $IXHL $MRM $LPSN $BSLK $GNS $Xbi $OPEN $CARM $ORIS $GSIW $RAYA $ADAP $ATCH $Bini $LPTX $INTS $IMAB -Leerink initiates I-Mab coverage at Outperform $9 target - $INN -Baird lowers Summit Hotel target to $4.50 from $5 Neutral - $INSM -Goldman Sachs raises Insmed stock to $196 from $121 Buy - $IVZ -BMO initiates Invesco coverage at Outperform $28 target - $IMAB -Leerink initiates I-Mab coverage at Outperform $9 target - $INN"
X Link 2025-10-09T19:33Z [----] followers, [----] engagements

"$ABP stock price .1815 $15m MCAP $IMAB stock price $6 $700 MCAP $IMAB Givastomig Claudin 18.2- gastric cancer $ABP -ABP-150 Claudin [----] gastric cancer Both target the same proteinsClaudin [----] on tumor cells and 4-1BB or CD3 on T-cell $XBI $LPTX $IXHL $AZI $ABP $16M market cap Developing ABP-150 Claudin [----] in Gastric cancer $IMAB stock price increased from .60 to $5.90 based on givastomig Claudin18.2 asset in gastric cancer $IXHL $MRM $LPSN $BSLK $GNS $Xbi $OPEN $CARM $ORIS $GSIW $RAYA $ADAP $ATCH $Bini $LPTX $INTS https://t.co/8FxiIqyqQQ $ABP $16M market cap Developing ABP-150 Claudin"
X Link 2025-10-13T15:36Z [----] followers, [----] engagements

"$GLMD its sad what the market makers can do In [--] minutes only [---] shares traded since 9:32 $OPTX $HIHO $TRIB $VIVK $HXHX $SOC $WOK $HXHX $PAVS $FULC $WKHS $CETX $TWG $TGL $VCIG $AZI $XBI $SGBX"
X Link 2025-12-23T15:17Z [----] followers, [----] engagements

"$GLMD still holding and I have no sold any shares. Its pathetic only [-----] shares traded today Hopefully the company will announce news January [----] $OPTX $HIHO $TRIB $VIVK $HXHX $SOC $WOK $HXHX $PAVS $FULC $WKHS $CETX $TWG $TGL $VCIG $AZI $XBI $SGBX $GLMD its sad what the market makers can do In [--] minutes only [---] shares traded since 9:32 $OPTX $HIHO $TRIB $VIVK $HXHX $SOC $WOK $HXHX $PAVS $FULC $WKHS $CETX $TWG $TGL $VCIG $AZI $XBI $SGBX $GLMD its sad what the market makers can do In [--] minutes only [---] shares traded since 9:32 $OPTX $HIHO $TRIB $VIVK $HXHX $SOC $WOK $HXHX $PAVS $FULC"
X Link 2025-12-26T20:46Z [----] followers, [----] engagements

"$GLMD low float 5.5M shares OS Enters [----] with potentially many Catalysts #MASH potentially partnering Phase 1/2 clinical trial Aramchol and regorafenib in advanced gastrointestinal cancers including hepatocellular carcinoma $XBI $IBB $MRK $DVLT $GUTS"
X Link 2026-01-05T16:44Z [----] followers, [---] engagements

"$GLMD waiting patiently stock price ridiculously low 5.5M shares outstanding and huge upside potential Pipeline has $0 value Multiple assets: #MASH phase [--] ready Oncology asset $XBI $IBB $DVLT $GUTS $IVF $GLMD Im the largest individual investor. The company is worth at least $3.5 per share without the pipeline including Im long on the company $XBI $IBB $DVLT $GUTS $IVF $GLMD Im the largest individual investor. The company is worth at least $3.5 per share without the pipeline including Im long on the company $XBI $IBB $DVLT $GUTS $IVF"
X Link 2026-01-06T20:07Z [----] followers, [----] engagements

"$GLMD extremely low volume [----] shares traded so far. 5.5M shares outstanding/ $19.2M in cash Hopefully the company announces news soon. $XBI $IBB $DVLT $GUTS $IVF $GLMD waiting patiently stock price ridiculously low 5.5M shares outstanding and huge upside potential Pipeline has $0 value Multiple assets: #MASH phase [--] ready Oncology asset $XBI $IBB $DVLT $GUTS $IVF $GLMD waiting patiently stock price ridiculously low 5.5M shares outstanding and huge upside potential Pipeline has $0 value Multiple assets: #MASH phase [--] ready Oncology asset $XBI $IBB $DVLT $GUTS $IVF"
X Link 2026-01-08T16:12Z [----] followers, [---] engagements

"$GLMD holding full position low float any day could skyrocket: Cash in hand/$3 per share #MASH Pipeline is worth $0 which is ridiculous IMHO acquisition price target $10+ Will @MadrigalPharma acquire $GLMD $XBI $IBB $ATON $MDGL $VKTX $TERN $GLMD bullish news today went unnoticed. $MDGL is shifting into combination in #MASH indication $GLMD is ahead of other biotech companies already got patient approved with $MDGL Rezdiffra for the haters Im still the largest shareholder $XBI $IBB $DVLT $GUTS $IVF $OPEN $GLMD bullish news today went unnoticed. $MDGL is shifting into combination in #MASH"
X Link 2026-01-13T13:48Z [----] followers, [----] engagements

"$MREO Lead the pack in #AATD space & discontinuation continues terminated/discontinued Drugs in #AATD $VRTX discontinued VX-864/VX-814 $ALNY ALN-AAT02 $CNTA $NTLA NTLA3001 $BMRN latest victim 12/2025 Remaining companies AATD $MREO PH [--] ready $BEAM data in [--] $XBI $IBB $MREO Lead the pack in AATD space terminated/discontinued Drugs in #AATD $VRTX discontinued VX-864/VX-814 $ALNY ALN-AAT02 $CNTA $NTLA NTLA3001 Remaining companies AATD $MREO PH [--] initiation in [--] $BEAM data in [--] $WVE Data in [--] $KRRO Data in [--] $KRYS Data in [--] $XBI $MREO Lead the pack in AATD space terminated/discontinued"
X Link 2026-01-14T19:32Z [----] followers, [---] engagements

"$GLMD waiting patiently for skyrocket like $SHPH $GLMD 5.5M OS news could come any day $XBI $IBB $GLMD plenty of cash and no debt: 5.5M OS IMHO I expect similar move as $XAIR $ATON Im long on $GLMD $XBI $IBB $GLMD plenty of cash and no debt: 5.5M OS IMHO I expect similar move as $XAIR $ATON Im long on $GLMD $XBI $IBB"
X Link 2026-01-20T14:08Z [----] followers, [----] engagements

"$GLMD its ridiculous low volume. Very easy to manipulate the stock price. today volume [----] $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE How About comparing $GLMD $5.5M market cap Late stage #MASH vs $AKRO acquired for $5.2B or $ETNB acquired for $3.2Bn Its ridiculous how some stocks are extremely undervalued. $GLMD $5.5M $AKRO $5.2B $ETNB $3.2B Patiently waiting for some news in [----]. $XBI $IBB How About comparing $GLMD $5.5M market cap Late stage #MASH vs $AKRO acquired for $5.2B or $ETNB acquired for $3.2Bn Its ridiculous how some stocks are extremely undervalued."
X Link 2026-01-21T17:26Z [----] followers, [----] engagements

"$GLMD great article 👇 $GLMD Excellent article that nails exactly where GLMD stands right now. So if you want to update your GLMD knowledge or get acquainted with GLMD this is a must read. https://t.co/DSMVbpMwZv $GLMD Excellent article that nails exactly where GLMD stands right now. So if you want to update your GLMD knowledge or get acquainted with GLMD this is a must read. https://t.co/DSMVbpMwZv"
X Link 2026-01-21T19:16Z [----] followers, [---] engagements

"$GLMD from $32 PT & now stock price is trading below $.90 institutional investors included Baker Brothers were so bullish in Aramchol in #NASH The PT was $32 What happened company paused phase [--] due to funding not because of efficiency $XBI $ENTA $GPCR $IBRX $ADTX $GLMD $5.5M market cap dirt cheap The cheapest #MASH company With lead asset could be worth billion No debt and toxic warranties $19M in cash $KULR $SAFX $SRXH $SCNX $MTEN $IVP $RIME $IBRX $JTAI $GSIT $XBI $RARE $VKTX https://t.co/q8WP4TtQpA $GLMD $5.5M market cap dirt cheap The cheapest #MASH company With lead asset could be worth"
X Link 2026-01-23T13:24Z [----] followers, [----] engagements

"Extremely tiny float stocks: #1 $GLMD current price .82 $19M in cash as of 3rd qtr/ $3 per share #2 $HIND current price. $3 $5.71M in cash Both companies potentially have billion dollar drug I will give $GLMD hedge over $HIND because of strong balance sheet and no debt"
X Link 2026-01-27T16:28Z [----] followers, [----] engagements

"@DaddiMilton Please do me a favor dont post if you dont know what are you talking about"
X Link 2026-01-27T17:46Z [----] followers, [--] engagements

"$GLMD current stock price .81 raised $7M at average price of $2 per share. During the [--] months ended September [--] [----] we sold [-------] ordinary shares pursuant to the [----] Sales Agreement for a total net consideration of approximately $7.7 million $XBI $HIND $ADTX Extremely tiny float stocks: #1 $GLMD current price .82 $19M in cash as of 3rd qtr/ $3 per share #2 $HIND current price. $3 $5.71M in cash Both companies potentially have billion dollar drug I will give $GLMD hedge over $HIND because of strong balance sheet and no debt Extremely tiny float stocks: #1 $GLMD current price .82 $19M in"
X Link 2026-01-27T17:49Z [----] followers, [----] engagements

"$GLMD added more today $GLMD is trading well below cash on hand $3 per share: Current price .85 Cash on hand $19M Roughly $3 per share without value the pipeline $HIND $ADTX $MRNO $GLMD is trading well below cash on hand $3 per share: Current price .85 Cash on hand $19M Roughly $3 per share without value the pipeline $HIND $ADTX $MRNO"
X Link 2026-01-29T17:25Z [----] followers, [----] engagements

"$GLMD volume started to increase: 15K buy order $XBI $ENTA $GPCR $IBRX $ADTX $HIND $rimi $CRDF"
X Link 2026-01-29T19:15Z [----] followers, [---] engagements

"$GLMD current market cap is $4M and extremely undervalued -p [--] ready MASH drug -p 1/2 oncology asset Cash in hand /$3 per share vs current stock price of .69 $XBI $IBB $HIND $ADTX $MRNO $GLMD $6M market cap & $19.2M in cash -p [--] ready MASH drug -p 1/2 oncology asset The company trading negative enterprise value Cash in hand /$3 per share $TERN beginning of year was traded $1.87 and now trading $45 discontinued main obesity drug in October $XBI $IBB https://t.co/rIDlczsQo9 $GLMD $6M market cap & $19.2M in cash -p [--] ready MASH drug -p 1/2 oncology asset The company trading negative enterprise"
X Link 2026-02-02T17:57Z [----] followers, [---] engagements

"$MREO $137M MC 1) Setrusumab bone disease drug huge market opportunity 2) Alvelestate in #AATD lung disease bigger market than Cystic Fibrosis Vs $CINC $1.3B valuation only [--] drug Baxdrostate missed the primary endpoint in phase [--] $AZN should have acquired $MREO for $1B"
X Link 2023-02-16T16:39Z [----] followers, [----] engagements

"$GLMD Im the largest individual investor. The company is worth at least $3.5 per share without the pipeline including Im long on the company $XBI $IBB $DVLT $GUTS $IVF $GLMD 75% approx discount to its cash balance tax loss hammered in Dec Sitting on $19m in cash with mkt cap less than $5m only $1.5m a QUARTER cash burn https://t.co/T2Oed7yvdX $GLMD 75% approx discount to its cash balance tax loss hammered in Dec Sitting on $19m in cash with mkt cap less than $5m only $1.5m a QUARTER cash burn https://t.co/T2Oed7yvdX"
X Link 2026-01-05T21:50Z [----] followers, [----] engagements

"$MDGL @MadrigalPharma should acquire $GLMD @GalmedPharma for $100M $GLMD secured new patents for the Aramchol with Rezdiffra combination in #MASH $GLMD plans to engage with (FDA) on designing a Phase [--] trial for this combination $XBI $IBB $DVLT $GUTS $IVF $OPEN It appears that $MDGL will remain an independent company and build a pipeline behind Rezdiffra. The launch of the first MASH drug speaks for itself and the company's sales force. The price tag is simply too high but I like the company even without M&A deal. 👇 https://t.co/lkC5H5Ey8J It appears that $MDGL will remain an independent"
X Link 2026-01-09T13:52Z [----] followers, [----] engagements

"$GLMD Im shocked that stock price is .80 Late stage asset in MASH and phase [--] open label data shown 60% fibrosis reduction oral pill is good data. Potentially a billion drug and current market cap is $6M Patent granted for combo with $MDGL $XBI $ADTX $ENTA $IBB $GLMD Excellent article that nails exactly where GLMD stands right now. So if you want to update your GLMD knowledge or get acquainted with GLMD this is a must read. https://t.co/DSMVbpMwZv $GLMD Excellent article that nails exactly where GLMD stands right now. So if you want to update your GLMD knowledge or get acquainted with GLMD"
X Link 2026-01-21T15:28Z [----] followers, [----] engagements

"@DaddiMilton 😂 tiny means below 10M OS. $HIND 5.5M OS $GLMD [---] to 7M OS"
X Link 2026-01-27T18:44Z [----] followers, [---] engagements

"$ABP near break out & price target $4 1500% upside potential IMO PR soon 2nd qtr earnings is due by August [--] $IXHL $BTA $MRM $NCNA $LPSN $SGBX $IBG $TPIC $NLSP $OSCR $GNS $RAYA $CHSN $ABP $PLBL $RYVL $XBI $BSLK $ABP When PR drop this will be a runner IMO $ABP When PR drop this will be a runner IMO"
X Link 2025-08-13T18:30Z [----] followers, 12K engagements

"$ABP T-cell engager asset very valuable. current market cap of $22M is ridiculously low @AbbVie pens $1B deal for Simceres phase [--] T-cell engager $IXHL $BTA $MRM $NCNA $LPSN $SGBX $IBG $TPIC $NLSP $OSCR $GNS $BINI $XBI https://www.fiercebiotech.com/biotech/jpm25-abbvie-pens-1b-deal-simceres-phase-1-t-cell-engager $ABP the stock price should be trading $4 just on $ABBV Acquisition of Capstan Therapeutics @abbvie acquisition of Capstan Therapeutics for up to $2.1 billion great news for vivo CAR-T space stocks like $ABP $IXHL $BTA $MRM $NCNA $LPSN $SGBX $IBG $TPIC $NLSP $OSCR $GNS"
X Link 2025-08-19T14:57Z [----] followers, [----] engagements

"$ABP will be great target for big pharms. the valuation is dirt cheap @AbbVie 2nd deal for T-cell engager pays $65M with $1.4B chaserfor options on @evolveimmune T-cell engagers $IXHL $BTA $MRM $NCNA $LPSN $SGBX $IBG $TPIC $NLSP $OSCR $GNS $BINI $XBI https://www.fiercebiotech.com/biotech/abbvie-pays-65m-14b-chaser-options-evolveimmunes-t-cell-engagers https://www.fiercebiotech.com/biotech/abbvie-pays-65m-14b-chaser-options-evolveimmunes-t-cell-engagers"
X Link 2025-08-19T15:29Z [----] followers, [----] engagements

"$ABP +$3 acquisition price is bargain for big pharmaceuticals @GileadSciences to acquire Interius BioTherapeutics private company for $350M $IXHL $BTA $MRM $NCNA $LPSN $SGBX $IBG $TPIC $NLSP $OSCR $GNS $BINI $XBI $ABP $19M market cap: developing CAR T-cell therapy: valuation is ridiculously low Abpro pipeline is more advanced than Interius 👇 $GiLD / Kite to Acquire CAR T cell therapy Interius BioTherapeutics private company for $350M. $XBI $IXHL $OPEN $APM $PTIX $CYCU $GNS https://t.co/ckbRvFi7aQ $ABP $19M market cap: developing CAR T-cell therapy: valuation is ridiculously low Abpro"
X Link 2025-08-22T17:43Z [----] followers, [----] engagements

"$ABP 5X the current price $1.25 it seems high but valuation still remains dirt cheap Maxim group price target $4 $IXHL $BTA $MRM $NCNA $LPSN $SGBX $IBG $TPIC $NLSP $OSCR $GNS $BINI $XBI The Only Four Stocks You Need To 5x Your Account (Next Weeks Watchlist) 🚨 Lets see how fast we can get to [---] likes ❤ https://t.co/MA0gIXHVHX https://t.co/iOoLooV6NK The Only Four Stocks You Need To 5x Your Account (Next Weeks Watchlist) 🚨 Lets see how fast we can get to [---] likes ❤ https://t.co/MA0gIXHVHX https://t.co/iOoLooV6NK"
X Link 2025-08-25T18:09Z [----] followers, [----] engagements

"$ABP gone through [--] page of Form PRE 14A filed on 08/29/25 Im more bullish than before and stock price should have been up@ least 100% today im holding full position: you do you $IXHL $BTA $MRM $NCNA $LPSN $SGBX $IBG $TPIC $NLSP $OSCR $GNS $BINI $XBI https://investor.abpro.co/static-files/ab2a751b-219f-4cb7-a116-57a4b0bd2122 $ABP stock price should be up by a lot today: RS margins 1/10 the lowest margin that I have seen for pennies stocks: the annual meeting would not be for another 45-60 days: $CARM + 150% shares holders approved RS in 1/50 margin. $XBI $IXHL $HOTH"
X Link 2025-09-02T16:23Z [----] followers, [----] engagements

"$ABP strong finish today: hopefully ready for next leg up. $IXHL $BTA $MRM $NCNA $LPSN $SGBX $IBG $TPIC $NLSP $OSCR $GNS $BINI $XBI $ABP gone through [--] page of Form PRE 14A filed on 08/29/25 Im more bullish than before and stock price should have been up@ least 100% today https://t.co/EHcfGGxN0c im holding full position: you do you $IXHL $BTA $MRM $NCNA $LPSN $SGBX $IBG $TPIC $NLSP $OSCR $GNS $BINI $XBI $ABP gone through [--] page of Form PRE 14A filed on 08/29/25 Im more bullish than before and stock price should have been up@ least 100% today https://t.co/EHcfGGxN0c im holding full position:"
X Link 2025-09-03T20:15Z [----] followers, [----] engagements

"@NextTradeX 😂 [--] months away from 1st extension + potentially another [--] months extension $GLMD"
X Link 2026-02-02T17:00Z [----] followers, [--] engagements

"Biotech names forecasting huge revenue expansion next year: $MREO (+6363%) developing therapies for rare diseases and oncology with a focus on unmet medical needs. $DNLI (+3897%) targeting neurodegenerative conditions like Parkinsons and Alzheimers disease. $NTRB (+3394%) working on abuse-deterrent transdermal treatments and innovative drug delivery solutions. Big science. Big numbers. Big risk. https://twitter.com/i/web/status/2021625599291240816 https://twitter.com/i/web/status/2021625599291240816"
X Link 2026-02-11T16:41Z [--] followers, [----] engagements

"$ABP 👍 THE GOLDMAN SACHS GROUP INC purchased [---------] shares representing 6.8% ownership"
X Link 2026-02-10T03:37Z [----] followers, [----] engagements

"Cam kemik hastas bir bebein annesi ile oynad yatakta kayma oyunu"
X Link 2026-02-09T03:45Z 372.6K followers, 530.4K engagements

"$MREO: Ultragenyx has earnings call on Feb [--]. This is the first time they will be answering a broader group of analysts about Setrusumab failure and the path forward. They now had more than a month to analyze the data so hopefully we will know the plans forward"
X Link 2026-02-09T14:37Z [--] followers, [----] engagements

"🎥 #OncotargetShort: Abstract #video about this #research paper #published in Vol. [--] titled "The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo." @VCU 🔗 #cancer #TrendingWithImpact #tumors #oncology #oa https://doi.org/10.18632/oncotarget.28762 https://doi.org/10.18632/oncotarget.28762"
X Link 2025-12-19T19:00Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing